History has not been kind to PI3K inhibitors, but Scorpion Therapeutics, Inc. hopes that its mutant-selective PI3Kα inhibitor, STX-478, can do what most drugs in the class have not, which is show the high degree of efficacy that comes from targeting PI3K enzymes without the high degree of toxicity that comes with it.
The company said 16 July that it had closed a $150m series C financing round – co-led by Frazier Life Sciences and Lightspeed Venture Partners – that it plans to use to support the clinical development of the drug, which entered Phase I/II development in 2023 and is currently in multiple expansion cohorts in solid tumors, especially
Key Takeaways
-
Scorpion Therapeutics raised a $150m series C venture capital round that it plans to invest mainly in its Phase I/II mutant-selective PI3Kα inhibitor, STX-478.
-
The company is developing the drug as a monotherapy and in combination with CDK4/6 inhibitors and fulvestrant in patients with HR+/HER2- breast cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
